Health Plan Utilization and Costs of Specialty Drugs Within 4 Chronic Conditions

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres

“…347 Therefore, we performed a literature search for COI studies 348 for the period from January 2010 to December 2013 using 349 the same search terms and databases as Raho et al [9].Our 350 search identified a further nine publications [28][29][30][31][32][33][34][35][36], seven 351 of which involved psoriasis patients with biological treat-352 ment. In the COI analyses conducted by Fonia et al (UK) 353 [28] and Driessen et al (the Netherlands) [29] all patients 354 were treated with biological drugs.…”

“…The biological treat-355 ment rate was 16 % in the study by Ghatnekar et al 356 (Sweden) [34], 13 % by Levy and colleagues (Canada) 357 [33], 6 % by Steinke et al (Germany) [36] [32]. Only one study by Gleason and 359 colleagues (US) did not report the rate of biological therapy 360 [31]. 361 Studies that provided costs specifically for BST groups 362 or subgroups were selected for comparison.…”

“…361 Studies that provided costs specifically for BST groups 362 or subgroups were selected for comparison. Neither the 363 study by Gleason et al (US) [31] nor the one by Levy et al 364 (Canada) [33] reported costs data for BST group, therefore, 365 these were excluded. Moreover, only eight patients 366 received biological agent in the study by Steinke et al [36] Journal : Large [34] and Le Moigne (France, 2013) [32] 371 (Table 4).…”

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions

“…As biological therapies for inflammatory bowel disease become more common, the costs of caring for this patient population shift from hospitalizations and surgeries to medical therapy [114,115] considering the lower odds of hospitalization associated with biological drug use [116]. It is vitally important to understand that this new paradigm represents an ethically optimal change from reactive, illness-driven care to proactive, preventative care.…”

The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study (Preprint)

“…The financial burden accompanying MS is a central component of the disease experience, ranking second among all chronic conditions in direct costs behind congestive heart failure [3]. In addition to the impact of decreased productivity and unemployment [4][5][6], patients often shoulder the burden of high outof-pocket costs for medications, tests, MRIs, medical equipment, and inpatient/outpatient visits [3,7,8].…”